Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352209 | 0.92 | PTGER4 (0.59) | PTGER4ANPEPROCK2XIAPPOLB | |
| SCHEMBL5351605 | 0.91 | PTGER4 (0.49) | PTGER4ANPEPMAPK8MAPK9MAPK10 | |
| SCHEMBL5352224 | 0.91 | PTGER4 (0.58) | PTGER4ANPEPROCK2XIAPPOLB | |
| SCHEMBL5352243 | 0.91 | PTGER4 (0.58) | PTGER4ANPEPROCK2XIAPPOLB | |
| SCHEMBL6710706 | 0.85 | PTGER4 (0.46) | PTGER4 | |
| SCHEMBL14569820 | 0.85 | PTGER4 (0.42) | PTGER4ANPEPMAPK8MAPK9MAPK10 | |
| SCHEMBL6339372 | 0.82 | PTGER4 (0.46) | PTGER4 | |
| SCHEMBL6346170 | 0.81 | KDM4E (0.41) | PTGER4ANPEPROCK2CTSLCTSS | |
| SCHEMBL6347395 | 0.81 | PTGER4 (0.51) | PTGER4 | |
| SCHEMBL5350571 | 0.81 | PTGER4 (0.75) | PTGER4CMA1XIAPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196198-B2 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040235955-A1 | Remedies for pruritus | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040127487-A1 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-07-01 | — | — | US | disclosed |
| EP-1426059-A1 | REMEDIES FOR PRURITUS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6710205-B2 | ANTIALLERGENS; ANTICANCER AGENTS; AUTOIMMUNE DISEASES; BONE DISORDERS; RHEUMATIC DISEASES; ANTIULCER AGENTS; SKIN DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030114435-A1 | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1314719-A1 | BENZOIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1258473-A1 | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002493-A1 | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | PTGER1, PTGER4, PTGES | PTGER4 2/4885ANPEP 3070/4885MAPK8 2598/4885 |
| US-20030114435-A1 | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient | ALOX5, PDGFRB, ALOX15B | PTGER4 71/4885ANPEP 4495/4885MAPK8 2816/4885 |
| US-20040235955-A1 | Remedies for pruritus | PTGER3, PTGER2, PTGER1 | PTGER4 8/4885ANPEP 2195/4885MAPK8 1422/4885 |
| US-20040127487-A1 | Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | PDGFRB, ALOX5, ALOX15B | PTGER4 114/4885ANPEP 4529/4885MAPK8 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.